Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Nab-Paclitaxel, and AM RF EMF in Metastatic Pancreatic Cancer
NCT06576115Phase 2Recruiting
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in pancreatic adenocarcinoma (PDAC), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: 6 Month Progression-Free Survival Rate. Started Feb 2025; status: recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06576115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06576115.